SEC For		_														
	FORM	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL		
Check this box if no longer subject to STATEMEI					NT OF CHANGES IN BENEFICIAL OWNER							RSHIP		Numbe	r:	3235-0287
Section 16. Form 4 or Form 5 obligations may continue. See															erage burder	n 0.5
					d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940							hours per response:			0.5	
1. Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol							5. Relationship of Report (Check all applicable)			on(s) to Issu	Jer
Desai Neil					Aadi Bioscience, Inc. [AADI]							X Director X 10% Owner				vner
													give title		Other (s	specify
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year)							below)	Executiv	e Cha	below)	
C/O AADI BIOSCIENCE, INC. 17383 SUNSET BOULEVARD, SUITE A250					01/03/2023							1	JAccutiv	e ena	iiiiiuii	
17383 8	UNSET BO	ULEVARD, SU														
(Street)				[4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable e)				
PACIFIC CA 90272												X Form filed by One Reporting Person				
PALISADES												Form filed by More than One Reporting				
(City) (State) (Zip)												Person				
(City)	(5	state)	(Zip)													
		Та	ble I - Non-	Deriva	tive Se	ecuritie	s Ac	quired, D	isposed	of, or Be	neficiall	y Owned				
1. Title of Security (Instr. 3) 2. Transa Date				2. Transac	action 2A. Deemed Execution Date,					ities Acquir d Of (D) (Ins		5. Amoun Securities			n: Direct I or Indirect I	7. Nature of Indirect
			(Month/E		y/Year)	if any (Month/Day/Yea		Code (Ins	str.	:		Beneficiall Owned Fol		(D) or		Beneficial Ownership (Instr. 4)
								Code V	/ Amount	(A) o (D)	r Price	Reported Transaction(s)				
									Allount	(D)	Filce	(Instr. 3 a	d 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Ye	Cod	saction e (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable an Expiration Date (Month/Day/Year)		7. Title an of Securit Underlyin Derivative (Instr. 3 ar	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Cod	e V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)			
Stock option (right to buy)	\$12.31	01/03/2023		Α		150,000		(1)	01/03/2033	Common Stock	150,000	\$0.00	150,0	00	D	

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the total shares subject to the option shall vest each month thereafter on the same day as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month) such that all shares of common stock subject to the option shall be fully vested on the four year anniversary of the Vesting Commencement Date. "Vesting Commencement Date "shall mean January 1, 2023.

Remarks:

/s/ Stephen Rodin, as Attorney-01/04/2023

in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.